Background and objective:Analysis of inflammatory biomarkers, along with the neutrophil/lymphocyte ratio (NLR) or platelet/lymphocyte ratio (PLR), supports the connection between inflammation and carcinogenesis.Methods:We conducted a retrospective observational study at the Clinical County Hospital Mureș involving patients with lung cancer. The parameters analyzed included histopathological type (NSCLC: squamous cell carcinoma or adenocarcinoma; SCLC), molecular mutations (EGFR, ALK, PD-L1), parameters from the complete blood count, inflammatory parameters, and associated comorbidities.Results:A total of 380 patients were included: 115 patients in the cancer group and 265 patients in the control group. Among patients in the lung cancer group, 88 were diagnosed with NSCLC (44 adenocarcinomas, 44 squamous cell carcinomas) and 27 with SCLC. Both NLR and PLR were significantly higher in cancer patients than in the control group (5.30 versus 2.60,p< 0.001; 217 versus 136,p< 0.001, respectively). NLR and PLR differ between men and women (p= 0.005 andp= 0.056, respectively). C-reactive protein was not correlated with either NLR (p-value: 0.0669) or PLR (p-value: 0.6733) in lung cancer patients.Conclusions:The NLR and PLR values may serve as new predictive biomarkers for the diagnosis of disease in patients with lung cancer, especially those with NSCLC.
背景与目的：通过分析炎症生物标志物以及中性粒细胞/淋巴细胞比值（NLR）或血小板/淋巴细胞比值（PLR），可支持炎症与癌变之间的关联性。方法：我们在穆列什县临床医院开展了一项针对肺癌患者的回顾性观察研究。分析参数包括组织病理学类型（非小细胞肺癌：鳞状细胞癌或腺癌；小细胞肺癌）、分子突变（EGFR、ALK、PD-L1）、全血细胞计数参数、炎症参数及相关合并症。结果：共纳入380例患者：癌症组115例，对照组265例。肺癌组患者中，88例诊断为非小细胞肺癌（44例腺癌，44例鳞状细胞癌），27例为小细胞肺癌。癌症患者的NLR和PLR均显著高于对照组（分别为5.30比2.60，p<0.001；217比136，p<0.001）。NLR和PLR在性别间存在差异（分别为p=0.005和p=0.056）。肺癌患者中C反应蛋白与NLR（p值：0.0669）及PLR（p值：0.6733）均无相关性。结论：NLR和PLR值可作为肺癌（尤其是非小细胞肺癌）患者疾病诊断的新型预测性生物标志物。
肿瘤(癌症)患者之家